Skip to content
Screener

Pfizer PFE Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$16.7BBeat by $155.9M
EPS$0.87Beat by $0.24
Revenue estimate$16.5B
EPS estimate$0.63

Next report

Nov 3, 2026 (in a month)
Revenue estimate$15.9B
EPS estimate$0.77

Financials

Q3 2025

Income statement

See full
Revenue$16.7B-5.9%
Gross profit$12.5B+0.3%
Net income$3.5B-20.7%
EPS (diluted)$0.62-20.5%

Balance sheet

See full
Cash & equivalents$1.4B+21.0%
Total debt$61.7B-0.1%
Total equity$92.8B+0.6%
Total assets$208.73B-4.9%

Cash flow

See full
Operating cash flow$4.6B-31.4%
CapEx$602.0M-7.5%
Free cash flow$4.0B-34.0%

Valuation & ratios

Valuation

as of 09/28/25
See full
Market cap$144.87B-11.7%
Enterprise value$205.13B-8.7%
P/E14.7×—
P/S2.3×-0.4×

Profitability

See full
Gross margin73.4%+5.7pp
Net margin15.7%—

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.3×+0.3×

Segments

By product

See full
Eliquis$2.0B+24.6%
Prevnar Family$1.7B-3.4%
Vyndaqel family$1.6B+10.0%
Comirnaty$1.2B-19.1%
Ibrance$1.1B-2.8%

By geography

See full
International Developed Markets$3.7B+8.3%
International Emerging Markets$2.3B+1.8%

By segment

See full
Biopharma$16.3B-6.2%

FAQ

When did Pfizer report Q3 2025 earnings?
Pfizer (PFE) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Pfizer's Q3 2025 revenue and EPS?
Pfizer reported revenue of $16.7B and eps of $0.87 for Q3 2025.
Did Pfizer beat estimates in Q3 2025?
Revenue beat the consensus estimate of $16.5B by $155.9M. EPS beat the consensus estimate of $0.63 by $0.24.
How did Pfizer's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 5.9% from $17.7B a year earlier and eps declined 17.9% from $1.06.
Where can I find Pfizer's Q3 2025 SEC filings?
You can read the 8-K earnings release (0000078003-25-000149) and the 10-Q periodic report (0000078003-25-000150) directly on SEC EDGAR. The filing index links above go to sec.gov.